Chest
Original ResearchCritical CareQuality of Life, Pulmonary Function, and Tomographic Scan Abnormalities After ARDS
Section snippets
Materials and Methods
A detailed description of methods can be found in e-Appendix 1. Briefly, a prospective, observational, longitudinal study was carried out for 6 years in three ICUs in Barcelona, Spain. The study was approved by the ethics committee, and informed consent for participation was obtained initially from a next of kin and later confirmed by each patient.
During the study period, daily screening was performed of all patients admitted to the participating ICUs; those who met the criteria for ARDS6 were
General Characteristics of the Population Studied
A total of 204 patients were diagnosed with ARDS during the study period. The patient enrollment process is summarized in Figure 1. The study population consisted of 38 patients evaluated in the 6-month follow-up, representing 43.1% of those included. Only 15 patients were able to respond to the HRQL test at 1 month (39.4% of the total of patients assessed at 6 months). The main characteristics of the population included in the 6-month study, the survivors who could not be included, and
Discussion
To our knowledge, this is the first multicentric prospective study that evaluates quality of life, pulmonary function alterations, HRCT findings, and exercise test results in 6-month survivors of ARDS. The results show considerable alterations in HRQL in comparison with the healthy reference population. Moreover, most patients presented a mild restrictive pattern and Dlco decrease in PFT, accompanied by mild reticular alterations in CT scans and a moderate deficit in exercise capacity.
Conclusions
In summary, this study documented persistent alterations in HRQL at 6 months after critical illness, in comparison with a healthy reference population. Moreover, most patients presented mild/moderate radiologic and functional abnormalities. An early HRQL study in these patients enabled early detection of those who would present more 6-month HRQL morbidity. Therefore, early follow-up seems advisable, as well as performing follow-up after hospital discharge. These patients may benefit from
Acknowledgments
Author contributions: Dr Masclans: contributed to the conception and design of this study, acquisition of data, analysis and interpretation of data, and manuscript preparation.
Dr Roca: contributed to the acquisition of data, analysis and interpretation of data, and manuscript preparation.
Dr Muñoz: contributed to the conception and design of this study, acquisition of data, analysis and interpretation of data, and manuscript preparation.
Dr Pallisa: contributed to the conception and design of
References (35)
- et al.
Reference values for the 6-min walk test in healthy subjects 20-50 years old
Respir Med
(2006) - et al.
Six minute walk distance in healthy subjects aged 55-75 years
Respir Med
(2006) - et al.
Are results of the SF-36 health survey and the Nottingham Health Profile similar? A comparison in COPD patients
J Clin Epidemiol
(1997) - et al.
Long-term assessment of lung function in survivors of severe ARDS
Chest
(2003) - et al.
SUPPORT Investigators. Outcomes up to 5 years after severe acute respiratory failure
Chest
(2004) - et al.
Respiratory muscles, exercise tolerance and muscle training in COPD
Arch Bronconeumol
(2007) - et al.
Incidence and outcomes of acute lung injury
N Engl J Med
(2005) - et al.
Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study
Intensive Care Med
(2004) - et al.
Health-related quality of life
- et al.
Outcome measures for adult critical care: a systematic review
Health Technol Assess
(2000)
Pulmonary and extrapulmonary ARDS: are they different?
Rev Brasil Terap Intensiva
The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination
Am J Respir Crit Care Med
Spanish version of the Nottingham Health Profile: translation and preliminary validity
Am J Public Health
Standardisation of spirometry
Eur Respir J
Standardisation of the single-breath determination of carbon monoxide uptake in the lung
Eur Respir J
ATS Committee on proficiency standards for clinical pulmonary functional laboratories. ATS statement: guidelines for the six-min walk test in patients with chronic obstructive pulmonary disease
Am J Respir Crit Care Med
One-year outcomes in survivors of the acute respiratory distress syndrome
N Engl J Med
Cited by (97)
IL-22 Binding Protein Controls IL-22–Driven Bleomycin-Induced Lung Injury
2024, American Journal of PathologyCOVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases
2023, Respiratory InvestigationPathogenesis, Imaging, and Evolution of Acute Lung Injury
2022, Radiologic Clinics of North AmericaCitation Excerpt :If the patient survives the exudative and organizing phase of DAD, consolidation and GGO slowly improve. Although findings on CT may return to normal in a small percentage of patients,33 most patients have some degree of residual fibrosis because of mechanisms described previously.1 In most cases the fibrosis often involves less than 25% of the lung (see Figs. 1 and 2).33–35
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
2022, Translational ResearchCitation Excerpt :the estimated number of COVID-19 cases surpassing 180 million worldwide by mid-year 2021 and the proportion of most severe COVID-19 cases of approximately 5%, this will equate to millions of survivors of ARDS due to SARS-CoV-2. The mortality of ARDS has been reduced by the introduction of standardized management, including conservative fluid management45 and lung-protective ventilation,22 though there remains a subset of ARDS survivors who experience persistent pulmonary and extra-pulmonary consequences for years after recovery.46-49 Identified risk factors for increased severity of these long-term consequences include increasing age, the severity of the acute illness, duration of mechanical ventilation, and pulmonary-specific causes of ARDS.45
Long-term outcomes of EVALI: a 1-year retrospective study
2021, The Lancet Respiratory Medicine
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).